Mera Pharmaceuticals, Inc.
MRPI · OTC
10/31/2020 | 10/31/2011 | 10/31/2010 | 10/31/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.10 | -0.02 | 0.16 |
| FCF Yield | 0.00% | -6.77% | -10.33% | -1.85% |
| EV / EBITDA | 0.00 | -5.81 | -2.60 | -20.33 |
| Quality | ||||
| ROIC | 18.75% | 21.62% | 85.22% | 219.46% |
| Gross Margin | 0.00% | 94.63% | 84.05% | 95.32% |
| Cash Conversion Ratio | – | 0.38 | -0.02 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -20.36% | -22.05% | 8.40% |
| Free Cash Flow Growth | 0.00% | 47.59% | -179.80% | 57.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.02 | 0.01 | 0.02 |
| Interest Coverage | 0.00 | -34.60 | -110.52 | -44.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10,903.85 | -2,949.47 | -2,134.96 |